NCT03978351

Brief Summary

  1. 1.Evaluation of the role of serum midkine in differentiating malignant from benign thyroid nodule
  2. 2.studying the level of serum midkine in relation to different thyroid cancer stages

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
85

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 24, 2018

Completed
7 months until next milestone

First Posted

Study publicly available on registry

June 7, 2019

Completed
3 months until next milestone

Study Start

First participant enrolled

September 1, 2019

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

June 7, 2019

Status Verified

September 1, 2018

Enrollment Period

1.2 years

First QC Date

November 24, 2018

Last Update Submit

June 6, 2019

Conditions

Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

  • serum midkine levels

    Baseline

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study will be conducted on 85 informed and consented individuals (according to the guidelines of ethical committee of faculty of Medicine, Assuit University ) The study will include 30 patients with thyroid cancer and 30 patients with benign thyroid diseases. The study will also include 25 aged matched apparently healthy individuals as a control group.

You may qualify if:

  • patient with thyroid nodule

You may not qualify if:

  • Other known organ tumour
  • Chemothyrapy
  • Radiothyrapy c. Sample Size Calculation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Central Study Contacts

Marwa Hassan, Master

CONTACT

01004748373meromoro1010@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

November 24, 2018

First Posted

June 7, 2019

Study Start

September 1, 2019

Primary Completion

November 1, 2020

Study Completion

December 1, 2020

Last Updated

June 7, 2019

Record last verified: 2018-09